A Genetic Origin? Purpura Fulminans

Am J Med. 2019 Mar;132(3):327-328. doi: 10.1016/j.amjmed.2018.10.003. Epub 2018 Oct 24.

Authors

Orly Avnery¹, Gili Kenet², Martin H Ellis³

Affiliations

¹ Hematology Institute, Meir Medical Center, Kfar Saba, Israel; Sackler School of Medicine, Tel Aviv, Israel. Electronic address: avneryho@clalit.org.il.
² Sackler School of Medicine, Tel Aviv, Israel; National Hemophilia Center and Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel.
³ Hematology Institute, Meir Medical Center, Kfar Saba, Israel; Sackler School of Medicine, Tel Aviv, Israel.

PMID: 30367859
DOI: 10.1016/j.amjmed.2018.10.003

No abstract available

Keywords: Purpura fulminans; Thrombosis and mastectomy.

Publication types

Case Reports

MeSH terms

Activated Protein C Resistance / complications
Activated Protein C Resistance / diagnosis*
Activated Protein C Resistance / genetics
Activated Protein C Resistance / therapy
Anticoagulants / therapeutic use
Blood Component Transfusion
Breast
Debridement
Factor V / genetics*
Female
Glucocorticoids / therapeutic use
Heparin / therapeutic use
Humans
Mastectomy
Middle Aged
Plasma
Prednisone / therapeutic use
Protein S Deficiency / complications
Protein S Deficiency / diagnosis*
Protein S Deficiency / genetics
Protein S Deficiency / therapy
Purpura Fulminans / diagnosis*
Purpura Fulminans / etiology
Purpura Fulminans / genetics
Purpura Fulminans / therapy
Rivaroxaban / therapeutic use
Thigh
Vasculitis, Leukocytoclastic, Cutaneous / complications
Vasculitis, Leukocytoclastic, Cutaneous / diagnosis*
Vasculitis, Leukocytoclastic, Cutaneous / therapy

Substances

Anticoagulants
Glucocorticoids
factor V Leiden
Factor V
Heparin
Rivaroxaban
Prednisone

Supplementary concepts

Thrombophilia due to Activated Protein C Resistance